Life Science Marketing for Global Expansion from Asia

Life Sciences

In life sciences, developing a scientific breakthrough is only half the battle.

The companies that succeed understand that market approval (buy-in from stakeholders like KOLs, partners, and patients) must be built long before a new indication is ready to launch.

Whether you’re seeking licensing partners, preparing for commercialization, or scaling an existing portfolio, we help you engage the right voices, build the right evidence, and secure the right relationships at every stage of the development lifecycle.

De-risk your journey from lab to market with BDMT Global.

Your science is ready. Is your market strategy?

We have the right network and know-how to support your expansion.

Schedule a Complimentary Consultation

Why Life Sciences Needs Business Development (BD) and Marketing Transformation (MT)

For a long time, life science business development relied on relationship-building and scientific credibility, both essential. But in today’s market, that’s not enough.

Market leaders are leveraging modern marketing transformation to expand faster, communicate more effectively, and secure partnerships.

BD + MT combines deep scientific and industry expertise with the marketing capabilities needed to:

Engage KOLs throughout the product lifecycle, from early validation to post-launch advocacy
Communicate complex science to partners, investors, and stakeholders with clarity and impact
Build market credibility before regulatory approval, not after
Scale partnership efforts beyond the limits of traditional BD outreach

Learn More About Why BD + MT

Life Science Business Cases

Learn proven bio business development strategies from leaders at the world's leading pharma and biotech companies.

Horizon Therapeutics’ Focus on Local Community Movements Aids in $3B Annual Sales

How EQRx Conducted Strategic Branding Initiatives to Secure Pharmaceutical Supporters and Partners

Keytruda’s “Tru” Underdog Story: From Last on the Asset List to Merck’s Top Selling Product

Exploring Biogen’s Failed Crisis Response Efforts in 2019 and Their Current Repositioning Efforts in the Alzheimer's Community

View More Cases

End-to-End Services by U.S. Bio Team at BDMT Global

We support every stage of the deal lifecycle: scouting, valuation, negotiation, due diligence, and post-signing integration, among others.

Leverage our global network to find the right partners. We handle negotiations on your behalf, manage diligence to ensure no detail is missed, and develop transition plans that turn signed deals into realized value.

Our advisors are a group of senior level consultants who have worked with leading biotech and pharmaceutical companies and start-ups leading critical tasks such as drug development, deal transaction, post-deal integration, and more.

Work with BDMT’s marketing transformation specialists to accelerate meeting your goals by maximizing business opportunities.

1. Scouting

Using our extensive industry contacts, we can discuss your targeted needs, be it a product (in or out) or a company. Our network extends to both strategic sources (most focused in the bio-pharma area) as well as financial (Investment Banking, PE, and VC). Once given direction on your goals, we are able to perform an extensive search to either find the right partner(s) for your asset, or to find the type of asset you are seeking. We have worked in areas from technology platforms, early stage (PCC) products, to company acquisitions. Also notable, our network is global, covering both developed markets and emerging markets. We are glad to put our network to work for you!

2. Valuation

We have extensive experience in complex valuations, from patient based product valuation, to company-level DCFs. When needed, we support our models with expert managed market research to validate key assumptions. Our analytics have been validated by top-tier Investment Banks, PE firms, and well know Bio-pharma companies. Our personnel have done deals that were written up in The Wall Street Journal. In addition, we have broad therapeutic area expertise, so our analysis is not just hypothetical, but based on personal market knowledge.

3. Negotiation

If requested, we can either assist with negotiations (from Term Sheets through Asset Purchase Agreements), or run them on your behalf. Our team has negotiated all types of deals, from a simple technology license to company acquisitions. No deal is too small – or too large! We’ve handled both buy-side and sell-side deals, divestitures, and of course, global deals.

We can either work with your legal counsel, or help connect you with a firm that specializes in the area in which you are interested.

4. Due Diligence

While people often focus on the appeal of the negotiations, deals are usually made or broken during the diligence phase. Properly run diligence can change the value of the deal, or change the decision on whether to proceed.

On the sell side, we can help prepare and manage data rooms, and coordinate with buyers and their requests. On the buy side, we can manage the diligence process, and access subject matter experts if needed to supplement internal expertise.

It’s not just about getting a deal done, it’s about getting the right deal done!

5. Integration Planning

While everyone likes to celebrate “The Signing”, not everyone realizes that the work has just begun. How will the asset transfer and be integrated into the buyer’s portfolio? Who will need to be involved in the transfer? Will there be a Transition Services Agreement? Who will manage that? Fortunately we’ve developed these plans and can either create them and give them to you, or even supply people to manage the process after it has been developed.